Read the full company-by-company briefing, including final-day data, evidence context, and source links.
Read the comprehensive review ↗About this visual
Four obesity medicine updates around EASD 2026: retatrutide, CagriSema, EloraTZP and petrelintide, with findings on weight loss, glycemic control, appetite biology and tolerability.
Sources & further reading
These updates span different study phases, populations, durations, doses and analysis methods. Results are not head-to-head comparisons across trials. Additional context appears in the original LinkedIn post and discussion.




EASD 2026 has been a big week for obesity medicine!
A few updates stood out to me most:
🔹 Retatrutide | Eli Lilly and Company
The full Phase 3 TRIUMPH-1 results are now published.
At 80 weeks, retatrutide 12 mg produced 28.3% mean weight loss, with 45.3% losing at least 30% of their body weight.
TRIUMPH-2 was also impressive in people with obesity or overweight and type 2 diabetes: 20.8% mean weight loss and a 1.6% A1C reduction at 80 weeks. More than half no longer met BMI criteria for obesity, and up to 40% reached an A1C <5.7%.
🔹 CagriSema | Novo Nordisk
Some of the most interesting CagriSema data looked beyond weight loss alone.
At EASD, a 52-week fMRI study showed less hunger, cravings, food-related thoughts and “food noise,” along with changes in brain responses to high-calorie food cues.
REIMAGINE 1 MRI data also showed reductions in abdominal, liver and pancreatic fat.
Recent Phase 3 toplines also showed encouraging efficacy at the lower 1.0/1.0 mg dose:
• REDEFINE 9: 21.0% weight loss vs 2.0% with placebo
• REIMAGINE 5 in type 2 diabetes: 12.4% vs 9.1% with tirzepatide 5 mg, with similar A1C reductions
It will be interesting to see how dose flexibility becomes part of the CagriSema story.
🔹 EloraTZP | eloralintide + tirzepatide | Eli Lilly and Company
This was one of the biggest new readouts of the week.
In adults with obesity or overweight and type 2 diabetes, the top-dose combination of eloralintide 9 mg + tirzepatide 15 mg produced 23.3% mean weight loss at 48 weeks vs 14.8% with tirzepatide 15 mg alone.
A1C fell 2.9% vs 2.4%.
The efficacy is exciting, although tolerability will be important to follow. Adverse-event discontinuations ranged from 10.8% to 27.0% across the combination groups vs 2.9% with tirzepatide.
🔹 Petrelintide | Zealand Pharma & Roche
Petrelintide produced up to 10.7% mean weight loss at 42 weeks vs 1.7% with placebo in Phase 2.
The tolerability data may be just as interesting. GI adverse events were generally similar to placebo, and at the maximally effective dose there were no cases of vomiting or GI-related treatment discontinuations.
My biggest takeaway from EASD so far: Obesity treatment is quickly becoming much more than a GLP-1 story.
Triple agonists. (Retatrutide)
Amylin + GLP-1. (CagriSema)
Amylin + GIP/GLP-1. (Eloralintide + Tirzepatide)
Amylin monotherapy. (Petrelintide)
And we are increasingly looking beyond weight alone to appetite biology, glycemic control, visceral fat, tolerability and other health outcomes.
This is exactly the type of research I created Obesity Medicine Visuals to help organize and explain.
#ObesityMedicine #EASD2026 #ObesityResearch #GLP1